Form 4: Adaptive Biotechnologies Exec Trades Shares

Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, reported transactions involving the purchase and sale of company common stock under a Rule 10b5-1 trading plan.

Summary

• Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (ADPT), executed a series of transactions involving the company's common stock on April 1st and 2nd, 2026.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on November 18, 2025, which is designed to comply with affirmative defense conditions.
• Rubinstein acquired 14,722 shares of common stock on April 1st at a price of $7.27 per share and an additional 14,722 shares on April 2nd at the same price.
• Concurrently, Rubinstein sold 19,060 shares on April 1st at a weighted average price of $14.45 and 19,060 shares on April 2nd at a weighted average price of $14.60.
• Following these transactions, Rubinstein beneficially owns 466,262 shares directly as of April 2nd, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves significant share transactions by an executive, the execution under a Rule 10b5-1 plan suggests a pre-determined strategy rather than a reaction to new, undisclosed information.

Positives

• Transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less opportunistic trading activity.
• The acquisition of shares at $7.27 per share suggests a belief in the stock's value at that price point.
• The weighted average sale prices ($14.45 and $14.60) are significantly higher than the purchase price, indicating a profitable execution of the plan for the sold shares.

Negatives

• A significant number of shares were sold, which could be interpreted negatively by the market if not contextualized by the trading plan.
• The sale of shares, even under a plan, reduces the direct beneficial ownership of a key executive.

Risks

• The Rule 10b5-1 plan itself is subject to market conditions and the reporting person's ongoing assessment of the company's prospects.
• The weighted average sale prices indicate a range of selling prices, with some sales occurring at lower prices within the reported range, which could be a minor concern for specific transactions.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions executed under a trading plan.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
• The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.66, inclusive.
• The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
• The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.88, inclusive.
• The option is fully vested and exercisable.

Industry Context

StockSavvy.ai notes that insider trading reports, particularly those under Rule 10b5-1 plans, are common for executives in the biotechnology sector. These plans allow executives to buy or sell shares at predetermined times or prices, mitigating concerns about insider trading while still allowing for portfolio diversification or liquidity needs. The execution of such a plan by a President and COO in this sector is standard practice.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a plan, may lead to questions about the executive's confidence in the company's short-term prospects, although the purchase of shares at a lower price offers a counterpoint.
• Employees: May view the executive's transactions as a sign of company stability or potential, depending on their interpretation of the buy/sell activity.
• Creditors: Unlikely to be directly impacted by this type of transaction.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Adaptive Biotechnologies, ADPT, Stock Transaction, Beneficial Ownership, Executive Trading, Common Stock